Latest News - Phase 3/4 Trials

Monday, July 02, 2018

XELJANZ Receives EU Marketing Authorization for Adults with Active PsA

The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adul…

Read the full story

Friday, June 08, 2018

PellePharm Presents New Data in BCC

PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs a…

Read the full story

Friday, June 08, 2018

Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumab

Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) …

Read the full story

Tuesday, May 29, 2018

FDA Approves Cimzia for Moderate to Severe Plaque Psoriasis

The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment…

Read the full story

Wednesday, March 21, 2018

Sun Pharma: FDA Approves Ilumya for Adult Psoriasis

The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Il…

Read the full story

Thursday, February 15, 2018

Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meeting

Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include…

Read the full story

Monday, February 12, 2018

Denova Research and Illinois Dermatology Institute Partner for Clinical Research

DeNova Research is partnering with Illinois Dermatology Institute to become one of the largest and most comprehensive Dermatologic and Cosmetic Clinical Research sites in the Midwest. Denova Resear…

Read the full story

Monday, January 29, 2018

Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EB

The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy produ…

Read the full story

Wednesday, December 20, 2017

FDA Accepts NDA for Allergan, Paratek Acne Drug

The U.S. Food and Drug Administration accepted a New Drug Application (NDA) to review SeysaraTM(sarecycline) for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older,…

Read the full story

Tuesday, December 19, 2017

Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCC

Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of supe…

Read the full story

Tuesday, December 05, 2017

Revance: RT002 Achieves 6-Month Duration in Phase 3

  Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in …

Read the full story

Wednesday, November 08, 2017

Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors

Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and sympt…

Read the full story

Friday, October 27, 2017

Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studies

Top-line results from three pivotal Phase 3 clinical trials show that  risankizumab, an investigational interleukin-23 (IL-23) inhibitor, met the co-primary endpoints of at least a 90 percent imp…

Read the full story

Tuesday, September 26, 2017

Novan Has Guidance Meeting with FDA on SB204

Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which t…

Read the full story

Wednesday, September 20, 2017

Two-Year Data: TREMFYAâ„¢ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasis

New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate…

Read the full story
Load More